Sensei Biotherapeutics, Inc. (SNSE): Nasdaq/NYSE listing notice — Sensei Biotherapeutics receives Nasdaq deficiency notice for bid price below $1.00

Sensei Biotherapeutics, Inc.

Nasdaq notified Sensei on Oct 17, 2023 that stock bid price <$1 for 30 consecutive days, violating Listing Rule 5450(a)(1).
Company has 180 days (until April 15, 2024) to regain compliance by closing at $1.00+ for 10 consecutive business days.
Options include transferring to Nasdaq Capital Market or effecting a reverse stock split; company will monitor and consider remedies.
If not cured within compliance periods, Nasdaq will delist shares; company may appeal to a Hearings Panel.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Sensei Biotherapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

October 17, 2023, Sensei Biotherapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the minimum bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until April 15, 2024, to regain compliance

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Sensei Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-259994

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.